Stryker Co. (NYSE:SYK) VP M Kathryn Fink Sells 7,347 Shares

Stryker Co. (NYSE:SYK) VP M Kathryn Fink sold 7,347 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the transaction, the vice president now directly owns 10,042 shares of the company’s stock, valued at $3,685,213.16. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

M Kathryn Fink also recently made the following trade(s):

• On Friday, September 13th, M Kathryn Fink sold 2,121 shares of Stryker stock. The shares were sold at an average price of $370.00, for a total transaction of $784,770.00.

Stryker Stock Performance

Shares of SYK opened at $364.97 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.95 and a current ratio of 1.68. Stryker Co. has a twelve month low of $249.98 and a twelve month high of $374.63. The firm’s 50 day moving average price is $344.61 and its two-hundred day moving average price is $342.90. The firm has a market cap of $139.08 billion, a P/E ratio of 41.66, a PEG ratio of 2.87 and a beta of 0.91.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share for the quarter, beating analysts’ consensus estimates of $2.79 by $0.02. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The firm had revenue of $5.42 billion for the quarter, compared to analyst estimates of $5.40 billion. During the same quarter in the previous year, the firm posted $2.54 earnings per share. The business’s revenue was up 8.5% on a year-over-year basis. On average, analysts forecast that Stryker Co. will post 12 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be given a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date is Monday, September 30th. Stryker’s dividend payout ratio is presently 36.53%.

Analysts Set New Price Targets

Several equities analysts recently issued reports on SYK shares. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Monday. Wolfe Research began coverage on shares of Stryker in a research report on Tuesday, September 10th. They issued an “outperform” rating and a $405.00 price objective for the company. Barclays raised their price objective on shares of Stryker from $374.00 to $402.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. Stifel Nicolaus lowered their price objective on shares of Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Finally, Needham & Company LLC raised their price objective on shares of Stryker from $392.00 to $393.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Five equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $378.58.

Institutional Trading of Stryker

A number of institutional investors have recently made changes to their positions in the business. Heritage Wealth Management Inc. bought a new stake in shares of Stryker in the second quarter worth $1,206,000. Sanctuary Advisors LLC bought a new stake in shares of Stryker in the second quarter worth $19,301,000. Clear Rock Advisors LLC lifted its position in shares of Stryker by 1.4% in the second quarter. Clear Rock Advisors LLC now owns 10,426 shares of the medical technology company’s stock worth $3,547,000 after purchasing an additional 140 shares in the last quarter. Centennial Bank AR lifted its position in shares of Stryker by 106.7% in the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after purchasing an additional 48 shares in the last quarter. Finally, Sycomore Asset Management increased its holdings in Stryker by 149.9% during the second quarter. Sycomore Asset Management now owns 42,659 shares of the medical technology company’s stock worth $14,526,000 after buying an additional 25,589 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.